Factors predicting prolonged empirical antifungal treatment in critically ill patients. - Wikidata - wikimedia - TriplyDB

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

http://www.wikidata.org/entity/Q37699716

about

Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety.

P2860

Q47678193-C776A2F8-EA36-4D54-993B-A35EFA3B2B53 Q52575674-1B333CFB-6ACE-40B9-B6FF-CE7422B8CB88

P2860

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

http://www.wikidata.org/entity/Q37699716

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@en

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@nl

type

label

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@en

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@nl

prefLabel

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@en

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@nl

P1433

Q37699716-A0C73473-D7AB-4FCF-AA60-CCC09DD17E9D

P1476

Q37699716-69419CD7-1AA0-4D36-849A-6AAC5239E627

P2093

Q37699716-2A4A5F3C-1B82-4829-A711-282A2FBF6675

Q37699716-57434320-2DBC-48C3-8E7D-61C9505F1C47

Q37699716-6B6C9CC1-E76F-409D-8D9B-95F78D8FB642

Q37699716-70B8BF53-3D07-4B64-9461-DD39D9C7ACA7

Q37699716-A0864B3E-52B6-4179-B2B4-E5946866AAB2

Q37699716-CE551A3E-2E6B-4559-8033-91255DC91087

P2860

Q37699716-075B104C-CF25-47FA-AD72-11AFE137280A

Q37699716-0A6AA44E-9093-492C-AD36-32C972580D25

Q37699716-27E6AB4E-B244-4783-8EEB-2487CCD5B036

Q37699716-2D429977-07B3-4034-9C6E-14D335E6CB8C

Q37699716-3851CA6A-43F0-4F0A-A2F0-8B8B3FF2B374

Q37699716-50CFC1B0-89C5-44E5-9283-B202C767D366

Q37699716-5243BC13-9A67-470A-8686-5E507B80BB69

Q37699716-5A8EAFA0-EEE7-4B49-AF65-E8946E3FE4CA

Q37699716-5D969123-89B5-491A-96EF-B426BEC7B552

Q37699716-5DE828F5-DA69-4B8D-B926-216B356BAF84

P2888

Q37699716-0533C190-A204-4042-B11D-0B616203DB10

P304

Q37699716-B3EB9A0C-E2A9-413F-AADF-0035594BB9EE

P31

Q37699716-FDCA1334-0110-4AE1-AB90-16CA867EE756

P356

Q37699716-389E4897-73BA-478F-A230-6E9A2C4845BB

P478

Q37699716-B6827C99-E229-42C7-928D-913CA9AF948E

P50

Q37699716-5797E966-9C9C-49B7-B97A-726719CB3394

Q37699716-5E3858DB-C278-483F-A79C-81BD30B5A761

Q37699716-D45F5FC6-04E6-4DA0-97BB-69A1059F4532

P577

Q37699716-784386C5-139E-4AAA-8245-40AA01D40700

P5875

Q37699716-28378C62-6DF2-4DAA-A120-9F66015921C1

P6179

Q37699716-A64A15A0-F745-48AF-A2E8-8A54F5512C55

P698

Q37699716-3DDB5F9A-1F3B-4E48-AA84-8610DB07F1A2

P932

Q37699716-33B8B5D1-88E3-484B-A1F5-CDC6CB631566

P356

1476-0711-13-11

P1433

Annals of Clinical Microbiology and Antimicrobials

P1476

Factors predicting prolonged empirical antifungal treatment in critically ill patients.

@en

P2093

Amer Kalaoun

http://www.w3.org/2001/XMLSchema#string

Anne Baranzelli

http://www.w3.org/2001/XMLSchema#string

Dia Elmanser

http://www.w3.org/2001/XMLSchema#string

Frédéric Wallyn

http://www.w3.org/2001/XMLSchema#string

Mohamed Zein

http://www.w3.org/2001/XMLSchema#string

Olivier Bouton

http://www.w3.org/2001/XMLSchema#string

P2860

Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study.

β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study

A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study.

The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia.

Diagnosis of invasive candidiasis in the ICU.

Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index.

(1-3)-β-D-Glucan vs Galactomannan Antigen in Diagnosing Invasive Fungal Infections (IFIs)

Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan.

Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study.

ICU-acquired immunosuppression and the risk for secondary fungal infections.

P2888

1476-0711-13-11

P304

11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-0711-13-11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Erika Parmentier-Decrucq

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260756413

http://www.w3.org/2001/XMLSchema#string

P6179

1020485946

http://www.w3.org/2001/XMLSchema#string

P698

24621182

http://www.w3.org/2001/XMLSchema#string

P932

3984712

http://www.w3.org/2001/XMLSchema#string